Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"image","alt":"Quantum BioPharma","displaySize":"","headline":null,"caption":"Quantum BioPharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/afa2918fb4040d1890576b67ae88dcb3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XbswrLbZoNoT5isbohZcMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/afa2918fb4040d1890576b67ae88dcb3","width":300,"height":87}},"lazy":false},{"type":"text","content":"TORONTO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 will air, starting today, a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation.","length":357,"tagName":"p"},{"type":"text","content":"Top CTV News journalist and W5 investigative reporter Jon Woodward describes Part One of the series in an article entitled, “Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?” The series explores the phenomenon of “stock spoofing,” a market manipulation tactic that is illegal in both Canada and the United States, and the basis of a USD $700 million lawsuit by Quantum Biopharma against two of Canada’s largest banks CIBC and RBC.","length":476,"tagName":"p"},{"type":"text","content":"The first of three parts of the W5 investigative series can be viewed today on CTV News at: W5: MS research derailed by stock market spoofing: lawsuit","length":150,"tagName":"p"},{"type":"text","content":"Quantum BioPharma Chief Executive Officer Zeeshan Saeed commented, “We thank W5 for their important investigation into the illegal, but little known, practice of stock spoofing and some of its harmful effects on retail investors. Our goal has always been to bring Lucid-MS – a potentially game-changing drug that in animal studies has been shown to stop and even reverse the degradation of nerve cells (a hallmark of multiple sclerosis) giving back mobility and control to the body unlike any drug today for the benefit of millions of people around the world who courageously live with this progressive and debilitating disease. By shining a light on our experience with alleged stock market man...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B